BeiGene Announces Clinical Data on Tislelizumab and Zanubrutinib to be Presented at the 24th Congress of the European Hematol...
May 16 2019 - 9:00AM
BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage
biopharmaceutical company focused on developing and commercializing
innovative molecularly-targeted and immuno-oncology drugs for the
treatment of cancer, today announced data presentations on its
investigational anti-PD-1 antibody tislelizumab and its
investigational BTK inhibitor zanubrutinib from four posters at the
24th Congress of the European Hematology Association (EHA), taking
place June 13-16, 2019 in Amsterdam.
Poster Presentations:
Title: |
Tislelizumab (BGB-A317) for relapsed/refractory classical
Hodgkin lymphoma: updated follow-up efficacy and safety results
from a Phase 2 study |
Abstract Code: |
PF469 |
Session Title: |
Hodgkin lymphoma – Clinical |
Date: |
Friday, June 14 |
Time: |
17:30 – 19:00 (CEST) |
Lead Author: |
Yuqin Song, M.D., Ph.D. |
Title: |
Major responses in MYD88 wildtype (MYD88WT) Waldenström
Macroglobulinemia (WM) patients treated with Bruton Tyrosine Kinase
(BTK) inhibitor zanubrutinib (BGB-3111) |
Abstract Code: |
PF487 |
Session Title: |
Indolent and mantle-cell non-Hodgkin lymphoma – Clinical |
Date: |
Friday, June 14 |
Time: |
17:30 – 19:00 (CEST) |
Lead Author: |
Meletios A. Dimopoulos, M.D. |
Title: |
Updated safety and efficacy data in a Phase 1/2 trial of
patients with Waldenström Macroglobulinaemia (WM) treated with the
Bruton Tyrosine Kinase (BTK) inhibitor zanubrutinib
(BGB-3111) |
Abstract Code: |
PF481 |
Session Title: |
Indolent and mantle-cell non-Hodgkin lymphoma – Clinical |
Date: |
Friday, June 14 |
Time: |
17:30 – 19:00 (CEST) |
Lead Author: |
Judith Trotman, MBChB, FRACP, FRCPA |
Title: |
Pooled analysis of safety data from monotherapy studies of
the Bruton Tyrosine Kinase (BTK) inhibitor, zanubrutinib
(BGB-3111), in B-cell malignancies |
Abstract Code: |
PS1159 |
Session Title: |
Chronic lymphocytic leukemia and related disorders –
Clinical |
Date: |
Saturday, June 15 |
Time: |
17:30 – 19:00 (CEST) |
Lead Author: |
Constantine S. Tam, M.D. |
About BeiGene
BeiGene is a global, commercial-stage, research-based
biotechnology company focused on molecularly-targeted and
immuno-oncology cancer therapeutics. With a team of over 2,400
employees in China, the United States, Australia and Europe,
BeiGene is advancing a pipeline consisting of novel oral small
molecules and monoclonal antibodies for cancer. BeiGene is also
working to create combination solutions aimed to have both a
meaningful and lasting impact on cancer patients. BeiGene markets
ABRAXANE® (nanoparticle albumin-bound paclitaxel), REVLIMID®
(lenalidomide), and VIDAZA® (azacitidine) in China under a license
from Celgene Corporation.i
Investor
Contact
Media ContactCraig
West
Liza Heapes+1
857-302-5189
+1 857-302-5663ir@beigene.com
media@beigene.com
i ABRAXANE®, REVLIMID®, and VIDAZA® are
registered trademarks of Celgene Corporation
BeiGene (NASDAQ:BGNE)
Historical Stock Chart
From Mar 2024 to Apr 2024
BeiGene (NASDAQ:BGNE)
Historical Stock Chart
From Apr 2023 to Apr 2024